Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.
Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...
Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.
New research indicates that about one-quarter of patients with bladder cancer treated with radical surgery on curative intent have detectable levels of tumour cells circulating in their blood. The ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results